Samsara BioCapital — 2020 Investments
2 investments dated 2020 · listed companies and verified rows first · show all
Accelerating development of new genetic medicines for people with devastating neurological diseases.
New York, US
Cory Freedland(Director)Rachel McMinn(Executive Officer, Director)Stephen Biggar(Director)
Board seatRobert Baffi· per SEC Form D
A2 Bio develops precision CAR T-cell therapies using its Tmod cell engineering platform, supporting both autologous and allogeneic applications.
BiotechHealthtechAgoura Hills, US
Scott Foraker(Executive Officer, Director)Madhavan Balachandran(Director)Michael Gallo(Director)C. Alexander Kamb(Director)
BoardDavid Goeddel(Director)
Board seatSrini Akkaraju· per SEC Form D · $71.5M raise · filed Oct 2020
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.